We have previously reported that crosslinking HLA-DR directly induces programmed cell death of malignant B cells. The present study further characterizes the biochemical mechanism for HLA-DR-mediated programmed cell death of tumor cells. Phosphatidylserine exposure on the plasma membrane and propidium iodide incorporation occur with very rapid kinetics and are observed as early as 10 min after the induction of cell death with anti-HLA-DR. In striking contrast to anti-CD95, we observe no activation of caspase-3, -8, or -9 upon anti-HLA-DR addition. Furthermore, the irreversible caspase inhibitor Z-VAD.fmk also failed to inhibit anti-HLA-DR-mediated cell death, further supporting the conclusion that HLA-DR induces cell death via a caspase-independent mechanism. We demonstrate that anti-HLA-DR-induced cell death is instead associated with a rapid disruption of the inner mitochondrial transmembrane potential, DW m , a process that is significantly inhibited by Bcl-2 overexpression. Furthermore, we find that DW m disruption results in the selective release of apoptosis-inducing factor (AIF) from the mitochondria. We propose that AIF is acting to initiate the morphological and biochemical changes observed in HLA-DR-mediated cell death.
Introduction
Hu1D10 (Remitogent, apolizumab) is a humanized monoclonal antibody created for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Hu1D10 has been shown to bind to a polymorphic determinant of the MHC class II molecule HLA-DR that is expressed in approximately 60% of B-cell malignancies.
1,2 A phase I, dose-escalation trial in patients with relapsed Hu1D10 Ag + NHL has been completed and a phase I, doseescalation study in Hu1D10 Ag + B-CLL patients has been initiated. [3] [4] [5] In vitro studies have demonstrated that Hu1D10 and other HLA-DR-specific monoclonal antibodies can induce cell lysis through antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity. In addition, HLA-DR-specific monoclonal antibodies can induce programmed cell death in B-cell lymphoma cell lines. 1, 6, 7 The mechanism of how HLA-DR transmits the necessary intracellular signals that lead to apoptosis of B-cell lymphomas is not yet understood.
Apoptosis has been defined by stereotypic morphological changes especially evident in the nucleus where the chromatin condenses. Other typical features include phosphatidylserine exposure and cytoplasmic shrinkage. In its most classic form, apoptosis is characterized by the activation of caspases, especially caspase-3, which proteolytically cleave proteins essential for cell survival leading to membrane blebbling, disruption of the nuclear lamin network, and condensation of nuclear chromatin. 8 Furthermore, caspases have been shown to activate endogenous endonucleases that cleave DNA into small oligosomal fragments. However, evidence from an increasing number of studies, using broad-spectrum caspase inhibitors, demonstrates that programmed cell death can also proceed in a caspase-independent manner where cells exhibit many, but not all, of the hallmark phenomena associated with classical apoptosis. 9 Interestingly, EM studies show that cells treated with pan-antibodies specific for HLA-DR exhibit many of the classical hallmarks of apoptosis, such as phosphatidylserine exposure and cellular condensation. 10 However, caspase activation is not detected in HLA-DR-mediated cell death in lymphoma cells. 6 The disruption of mitochondrial function plays a pivotal role in determining cellular commitment to apoptosis. The early stage of the apoptotic process is characterized by the breakdown of the inner mitochondrial transmembrane potential (DC m ). The loss of DC m is mediated by opening of mitochondrial permeability transition (PT) pores and is thought to represent a point of no return in committing the cell to undergo apoptosis. In the classical mechanism of apoptosis, loss of DC m results in the release of cytochrome c from the mitochondria ultimately leading to the formation of the cytochrome c/Apaf1/caspase-9 apoptosome and then caspase activation. 9, 11 Recently, it has been demonstrated that a second mediator of cell death, apoptosis-inducing factor (AIF), is also released from the mitochondria after apoptotic stimuli through the opening of PT pores and this molecule may mediate programmed cell death even in the absence of caspase activation. 12 When microinjected into cells in the presence of caspase inhibitors, recombinant AIF induces similar cellular changes as those observed during caspase-independent cell death. 13 In the present study, we further characterize the apoptotic pathways initiated by HLA-DR. Antibody binding to HLA-DR induces programmed cell death with extremely rapid kinetics, and the cell death pathway does not involve in the activation of caspases. Instead, we find that HLA-DR-mediated cell death is associated with a rapid loss of mitochondrial DC m and the release of the mitochondrial AIF, but not cytochrome c, from the inner membrane space of the mitochondria.
Material and methods

Cells and reagents
Raji cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in RPMI with 10% FCS. The acute lymphocytic leukemia (ALL) cell line ALL-697 was a gift from Dr John C Reed (Burnham Institute, Cancer Research Center, La Jolla, CA, USA) and were maintained in RPMI with 10% FCS and L-glutamine.
The inhibitor Z-VAD.fmk was purchased from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA, USA). Hu1D10, the pan-HLA-DR-a antibody L243, the pan-HLA-DR-b antibody L227, and the anti-CD20 antibody B1 were prepared as described. 1 The following antibodies were also used: antihuman CD95 (FAS) (Upstate Biotechnology, Lake Placid, NY, USA), anti-AIF (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Her2 (ATCC), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and HRP-conjugated donkey antigoat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), goat anti-human IgG, Fcg specific (Jackson ImmunoResearch Laboratories), anti-poly ADP-ribose polymerase (PARP) (Santa Cruz Biotechnology), and anti-cytochrome c (Chemicon International, Inc., Temecula, CA, USA).
Apoptosis assay
Raji cells (2 Â 10 5 cells/ml) in RPMI/10% FBS were pretreated with or without Z-VAD.fmk for 1 h prior to induction of apoptosis. Apoptosis was induced by the addition of Hu1D10 (0.1-5 mg/ml), L227 (0.1-5 mg/ml), L243 (0.1-5 mg/ml), or anti-CD95 (2 mg/ml) to the cultures. Cells were incubated for various times at 371C. Cells were washed twice with cold PBS and 100 ml of propidium iodide (PI) (Molecular Probes) and fluorescein-5-isothiocyanate (FITC)-conjugated annexin V in binding buffer was added according to the manufacturer's instructions (R&D Systems, Mt Prospect, IL, USA). After incubation for 15 min at room temperature, 400 ml binding buffer was added, and the samples were immediately analyzed on a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems (BDIS), Palo Alto, CA, USA). Data were collected and analyzed with CellQuest software (BDIS). Apoptotic events were considered to be annexin V-positive and PI-negative/ positive.
Caspase activity assays
Caspase-3 activity was analyzed with the Caspase-3 Apoptosis Detection Kit according to the manufacturer's protocol (Santa Cruz Biotechnology). Briefly, cells (2 Â 10 5 cells/ml) were treated for various times with 5 mg/ml Hu1D10 or 2 mg/ml anti-CD95. Cells were harvested at the indicated time points after the induction of apoptosis and cell lysates were prepared. Caspase-3 activity was measured by the addition of the substrate AspGlu-Val-Asp (DEVD)-AFC (7-amino-4-trifluoromethyl coumarin) to the cell lysates. Active caspase-3 cleaves the peptide substrate releasing the fluorophore AFC. Free AFC emits a yellow-green fluorescence at 480-520 nM upon excitation at 400 nM.
Caspase-8 activity was analyzed with the Caspase-8 Colorimetric Protease Assay Kit (Chemicon International, Inc.). To measure the activity of caspase-8, the substrate Ile-Glu-Thr-Asp (IETD)-pNA (p-nitroanilide) was added to the prepared cell lysates. Active caspase-8 cleaves the peptide substrate releasing the chromophore pNA. The pNA light emission was quantified at 405 nM.
Caspase-9 activity was analyzed with the Caspase-9 Colorimetric Protease Assay Kit (Chemicon International, Inc.). To measure the activity of caspase-9, the substrate Leu-Glu-His-Asp (LEHD)-pNA was added to the prepared cell lysates. Active caspase-9 cleaves the peptide substrate releasing the chromophore pNA. The pNA light emission was quantified at 405 nM.
PARP cleavage assay
Raji cells (5 Â 10 6 ) were treated with either Hu1D10 (5 mg/ml) or anti-CD95 (2 mg/ml). Whole-cell lysates (WCLs) were prepared for various time points by lysing the cells in lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% deoxycholic acid, 10 mg/ml aprotinin, 10 mg/ml leupeptin. Cells were incubated on ice for 60 min, followed by centrifugation for 5 min at 14 000g, at 41C. The cytosolic fraction was collected and 100 ml of the WCL was resolved on a 10% SDS-polyacrylamide gel (PAGE) then electrotransferred onto an Immobilon-P membrane (Millipore, Bedford, MA, USA). The blot was then probed with anti-PARP followed by HRP-conjugated goat anti-mouse IgG. The membrane was developed using enhanced chemiluminescence (ECL, Amersham Pharmacia, Piscataway, NJ, USA).
Evaluation of mitochondrial membrane potential
Cells (1 Â 10 6 cells/ml) were treated with Hu1D10 (5 mg/ml) or anti-CD95 (2 mg/ml) for various times at 371C. The cells were rinsed twice with PBS and were resuspended in 1 ml PBS. Cells were incubated in 1 mg/ml rhodamine 123 (Molecular Probes, Eugene, OR, USA) for 5-30 min at 371C, in the dark. Cells were then incubated with 20 mg/ml PI (Molecular Probes) for 5 min at room temperature, in the dark. Cells were washed and resuspended in 1 ml PBS and were then analyzed on a FACScan flow cytometer (BDIS). Data were collected and analyzed with CellQuest software (BDIS).
AIF/cytochrome c release Cells (1.5 Â 10 7 cells/ml) were treated with Hu1D10 (5 mg/ml) for various times at 371C. Cytosolic extracts were collected by washing the cells in PBS and resuspending them in 500 ml icecold homogenization medium containing 0.25 M sucrose, 0.5 mM EGTA, 5.0 mM HEPES, pH 7.2, 1 mM PMSF, 12.5 mg/ml aprotinin, and 12.5 mg/ml leupeptin. Cells were incubated on ice for 60 min and then were homogenized using 20 strokes of a Dounce homogenizer. The resulting lysates were centrifuged for 10 min at 41C at 2000 g. The resulting supernatant was collected and was centrifuged for 20 min at 41C at 20,000 g. The resulting supernatant was collected as the cytosolic fraction was resolved on a 15% SDS-PAGE, and then electrotransferred onto an Immobilon-P membrane (Millipore). The membrane was probed with anti-AIF followed with donkey HRP-conjugated anti-goat IgG or anti-cytochrome c followed by HRP-conjugated goat anti-mouse IgG. The blot was developed using ECL. Cytochrome c release was also detected using a Cytochrome C ELISA Kit per manufacturer's directions (Chemicon International, Inc.).
Alternatively, cells were treated for various times with 2-5 mg/ml Hu1D10 or anti-CD95. Cells were briefly permeabilized with 0.03% digitonin. This concentration of digitonin is enough to permeabilize the outer membrane of the cells without affecting the mitochondrial membrane. Cells were then fixed with 4% paraformaldehyde. Cells were incubated with an anti-AIF antibody that had been directly conjugated with the fluorophore Alexa 488 (Molecular Probes). AIF release was measured by flow cytometry.
Results
The kinetics of HLA-DR-mediated programmed cell death is rapid
Anti-HLA-DR antibodies can induce cell death in B cells and Bcell tumor lines. 1, 6 In a standard apoptosis assay that measures the binding of annexin V and PI to dying cells, we analyzed the kinetics of HLA-DR-mediated programmed cell death in Raji cells. These studies revealed an increase in annexin V binding and PI staining that was detectable as early as 30 min after treatment with anti-HLA-DR ( Figure 1 ). After a 5 h treatment, the percentage of Raji cell death was about 70%. An isotypematched control antibody does not induce Raji cell death. 1 In addition, we investigated whether antibody concentration influences the phenotype of cells undergoing HLA-DR-mediated cell death. It has been reported that even at high antibody concentrations, cells treated with antibodies specific for HLA-DR exhibit an apoptosis-like morphology characterized by chromatin condensation and cellular shrinkage. 10 We find in a dose-response study where antibody concentration increases from 0.1 to 5 mg/ml, the transition from live cells to annexin V positive cells only accelerates (data not shown). We find no evidence of morphology differences dependent upon antibody concentration. Hu1D10-mediated apoptosis is caspase independent. (a) Raji cells were preincubated with or without the pan-caspase inhibitor Z-VAD.fmk (50 or 300 mM) for 60 min at 371C. Hu1D10 or anti-CD95 (FAS) (2-5 mg/ml) was added to the culture and cells were incubated for 5 h at 371C. Cells were then stained with FITCconjugated annexin V and PI. Flow cytometry was used to assess percentage of cell death (annexin V-positive and PI-positive/negative cells). Alternatively, cells were harvested at the indicated time points after the induction of apoptosis and cell lysates were prepared to measure the activity of various caspases. (b) Caspase-8 activity was measured by adding the substrate Ile-Glu-Thr-Asp (IETC)-pNA to the prepared cell lysates. Active caspase-8 cleaves the peptide substrate releasing the chromophore pNA and light emission was quantified at 405 nm. (c) Caspase-9 activity was measured by adding the substrate Leu-Glu-His-Asp (LEHD)-pNA to the cell lysate. Active caspase-9 cleaves the peptide substrate releasing the chromophore pNA and light emission was quantified at 405 nm. (d) Caspase-3 activity was measured by adding the substrate Asp-Glu-Val-Asp (DEVD)-AFC to the cell lysate. Active caspase-3 cleaves the peptide substrate releasing the fluorophore AFC that emits a yellow-green fluorescence at 480-520 nm upon excitation at 400 nm. s.e.m. is shown for all figures.
-
HLA-DR-induced cell death is caspase-independent
Caspases are important executioners of programmed cell death, and activation of caspases is critical for the induction of apoptosis by receptors belonging to the tumor necrosis factor receptor family. 8, 14 To further elucidate the mechanism of HLA-DR-induced cell death, cells were pretreated with two concentrations of the cell permeable, broad-spectrum caspase inhibitor Z-VAD.fmk prior to treatment with either anti-HLA-DR or anti-CD95. CD95 was chosen as a control because of the extensive studies showing that antibodies against CD95 can induce apoptosis utilizing a caspase-dependent mechanism. As shown in Figure 2a , HLA-DR-induced cell death was not reduced by the pretreatment with either concentration of Z-VAD.fmk, while CD95-mediated apoptosis was completely inhibited, suggesting that HLA-DR-induced cell death is caspase-independent. B cells treated with the pan-HLA-DR antibody L243 also die utilizing a caspase-independent pathway. 6 Apoptosis induced by many different agents has been characterized by the activation of caspases and the subsequent cleavage of various substrates by the activated enzymes. We looked at the specific caspase activity of caspases -3, -8, and -9. Caspase-8 and -9 are known as 'initiator' caspases in the intrinsic and extrinsic pathways, respectively. Caspase-3, the common 'effector' caspase, is responsible for the cleavage of a variety of cellular protein substrates including PARP and lamins, which set into motion the biochemical and morphological changes that constitute the apoptotic process. 15 Cells were treated either with anti-HLA-DR or anti-CD95 for up to 5 h and then cell lysates were prepared and assayed for caspase activity ( Figure 2 ). As expected, caspase-8 activity was detected within 2 h after treatment with anti-CD95. In comparison, anti-HLA-DR-treated cells showed no caspase-8 activity (Figure 2b ). Caspase-9 activity was seen in the anti-CD95 treated cells in as early as 30 min after treatment, but not in the anti-HLA-DRtreated cells (Figure 2c) . Finally, anti-CD95-treated cells show specific caspase-3 activity 1 h after treatment, while no anti-HLA-DR-induced caspase-3 activity was detected (Figure 2d ). Taken together, these results suggest that in contrast to death receptor-mediated apoptosis, HLA-DR-induced programmed cell death does not require or involve the activation of caspase-3, -8 and -9.
PARP, an enzyme involved in DNA repair, is cleaved during apoptosis. 16 PARP in its native form is a 116 kDa protein that is cleaved by caspase-3 into a stable 85 kDa C-terminal protein fragment early in apoptosis. 17 Cleavage of PARP induced by ligation of HLA-DR or CD95 was assessed. The cleaved 85 kDa PARP fragment was not detected in the anti-HLA-DR treated WCLs even after the film had been exposed to very long exposure times (Figure 3, top) , whereas in the anti-CD95-treated samples, the 85 kDa cleavage product was readily detected as early as 2 h after treatment (Figure 3, bottom) . This again confirmed the absence of caspase activity in HLA-DR-induced cell death, specifically, the lack of caspase-3 activity, while in the anti-CD95-treated samples, appearance of the 85 kDa fragment coincides with the activation of caspase-3 (Figures 3  and 2d) . Treatment with Hu1D10 does not result in PARP cleavage. Raji cells were treated for various times with 2-5 mg/ml Hu1D10 or anti-CD95 (FAS). Cells were harvested at the indicated times (0-4 h) after the induction of apoptosis and WCLs were prepared. Samples were then subjected to SDS-PAGE and Western blotting with an anti-PARP antibody that is specific for the C-terminal portion of PARP present in the whole molecule and in cleavage products.
Figure 4
Hu1D10-mediated apoptosis results in mitochondrial depolarization. Raji cells were treated with 2-5 mg/ml Hu1D10 or anti-CD95 (FAS) for 0-4 h. The cells were harvested and stained with rhodamine 123. Flow cytometry was used to assess depolarization (decrease in fluorescence) vs swelling (increase in fluorescence) of the mitochondria. Experiment is representative of three repetitions.
Mitochondrial transmembrane potential is disrupted upon treatment with anti-HLA-DR
It has recently emerged that mitochondrial function plays a pivotal role in determining cellular commitment to survival or apoptosis by integrating an apoptotic signal and the activation of effector caspases. During apoptotic signaling, the mitochondrial inner membrane potential (DC m ) collapses, which is caused by the opening of a large conductance channel known as the mitochondrial PT pore. These events are associated with the release of several proteins that promote apoptosis. While the actual sequence of events that occur prior to the loss of DC m and the disruption of the mitochondrial membrane are not yet well understood, it is believed that the onset of mitochondrial dysfunction is the 'point of no return' in apoptosis. 11 Several types of membrane-permeable lipophilic cationic fluorochromes can be used as probes of DC m in flow cytometry. When live cells are incubated in their presence, the probes accumulate in mitochondria, and the extent of their uptake, measured by the intensity of the cellular fluorescence, reflects DC m . We investigated changes in mitochondrial transmembrane potential upon treatment with anti-HLA-DR or anti-CD95. We observed that within just 10 min of the addition of anti-HLA-DR, cells were already undergoing mitochondrial depolarization ( Figure 4 ). In addition, by examining early time points, we were able to observe shifts in DC m that represented swelling, which has been shown to occur early in the apoptotic process, prior to depolarization, and contributes to the disruption of the outer mitochondrial membrane. 18 In contrast, the anti-CD95-treated cells showed swelling of the mitochondria within the entire cell population that was followed by disruption of the mitochondria membrane potential 4 hours later. Thus, it seemed that cell death mediated by HLA-DR was associated with a rapid concomitant swelling and depolarization of mitochondria that correlated with the rapid kinetics of plasma membrane phospholipid flipping detected by annexin V binding. In contrast, the anti-CD95-treated cells showed initial swelling of the mitochondria followed by depolarization at a much later time point.
Anti-HLA-DR treatment induces the release of AIF from the mitochondria
The dissipation of the mitochondrial transmembrane potential is thought to commit a cell to death because of the increased permeability of the outer mitochondrial membrane, which in turn allows for the redistribution of mitochondrial factors, such as cytochrome c, into the cytosol, ultimately leading to the activation of effector caspases. [19] [20] [21] Since we have demonstrated that treatment with anti-HLA-DR resulted in no activation of caspases, we wanted to determine whether another mediator of cell death, AIF, was released from the mitochondria upon DC m disruption. During apoptosis induction by certain stimuli, AIF is released from the mitochondria to the cytosol and then rapidly translocates into the nucleus. Once localized to the nucleus, AIF induces peripheral chromatin condensation and large-scale DNA fragmentation. 12, 13 We therefore examined the presence of AIF in the cytosolic fractions of Raji cells treated with Hu1D10 for 10-60 min, times that coincided with the disruption of DC m . The release of AIF, but not cytochrome c, into the cytosol was observed after 30 min of anti-HLA-DR treatment (Figure 5a) . In a second ELISA assay specifically designed to detect cytochrome c release, we could readily detect cytochrome c release in cells treated with anti-CD95, but not with anti-HLA-DR-treated cells (Figure 5b ). To further support that AIF is released from the mitochondria after anti-HLA-DR treatment, we used anti-AIF and flow cytometry to Hu1D10 treatment results in the release of AIF from the mitochondria, but not cytochrome c. Raji cells were treated for various times with 2-5 mg/ml Hu1D10 or anti-CD95 (FAS). Cells were harvested at the indicated times after the induction of apoptosis and cytosol extracts were prepared. (a) WCL and cytosol extracts were then subjected to SDS-PAGE and Western blotting with anti-AIF or anticytochrome c antibodies. WCL was included as positive control for Western blotting. (b) Cytochrome c release was also measured in cytosolic extracts using a Cytochrome c ELISA Kit.
detect AIF in the cytosol of Raji cells ( Figure 6 ). To make the cytosol accessible to anti-AIF, we used 0.03% digitonin to make the cell membrane permeable to the antibody without affecting the mitochondria membrane. 22 Relocalization of AIF to the cytosol could be detected as 27.92% specific increase of fluorescence after treating Raji cells with anti-HLA-DR for 1 h. Anti-CD95, which caused no cell death at the 1 h time point, did not cause any relocalization of AIF. These data indicate that the Hu1D10-induced cell death is associated with the release of AIF from mitochondria.
Bcl-2 inhibits the ability of anti-HLA-DR to induce apoptosis
The Bcl-2 family, comprised of both pro-apoptotic and anti-apoptotic members, acts as a checkpoint upstream of mitochondria dysfunction. Many of the Bcl-2 family members reside in the mitochondrial outer membrane, anchored by a hydrophobic stretch of amino acids located within their carboxy-termini. 23 Bcl-2 family members are thought to govern functionally ion transport through the control of components of the PT pore. 18 Opening of the mitochondrial PT pore is one of the decisive events of the apoptotic process allowing for the release of proapoptotic factors. We therefore investigated the effects of overexpression of Bcl-2 on anti-HLA-DR-induced cell death in the ALL cell line ALL-697 that had been transfected with Bcl-2 (697/Bcl-2) or mock transfected with the expression vector alone (697/Neo). Western blot analysis determined that the 697/Bcl-2 cells expressed approximately five-fold more Bcl-2 than the parental cells line or mock-transfected cells (data not shown). Anti-HLA-DR-treated 697/Bcl-2 cells showed a significant reduction in the induction of phosphatidyl serine exposure, as detected by annexin V binding when compared to the mock-transfected 697/Neo (Figure 7a ). The protection offered by Bcl-2 was pronounced (annexin V binding was reduced by approximately 35%), although not complete. The protection of 697/Bcl-2 by Bcl-2 against spontaneous cell death by media or irrelevant antibody anti-Her2 is also evident. To further assess the role of mitochondria in HLA-DR-induced cell death, we tested whether Bcl-2 overexpression blocked mitochondria depolarization initiated by anti-HLA-DR treatment. Anti-HLA-DR-treated 697/Bcl-2 cells show a significant reduction (approximately 70%) in the disruption of DC m when compared to the mock-transfected 697/Neo (Figure 7b ). Finally, we tested the effect of Bcl-2 overexpression on AIF release from the mitochondria after anti-HLA-DR treatment (Figure 8 ). Anti-HLA-DR-treated 697/Bcl-2 cells show a modest reduction (approximately 25%) in AIF release when compared to the mock-transfected 697/Neo.
Taken together, these data demonstrate that Bcl-2 can inhibit the induction of anti-HLA-DR-mediated cell death and that this inhibition is associated with blocking the collapse of the mitochondria membrane potential. However, the release of AIF is not as significantly blocked by Bcl-2. Since the events that trigger AIF release have not been fully elucidated, it is possible that the Bcl-2 blockage of mitochondrial depolarization is downstream of AIF release, as has been shown previously for cytochrome c release. 24 Therefore, we conclude from this data that Bcl-2 must protect cells from death by mechanisms that counteract the effects of AIF release.
Discussion
This study was aimed to elucidate the mechanism of cell death induced by HLA-DR. We demonstrated that HLA-DR-mediated cell death occurred via a rapid, caspase-independent mechanism characterized by PS exposure, mitochondrial depolarization, and release of AIF from the mitochondria. Several lines of evidence support this proposed mechanism of anti-HLA-DRinduced cell death. First, the kinetics of HLA-DR-mediated cell death is more rapid than anti-CD95-mediated cell death and is not inhibited by the presence of the pan-caspase inhibitor Z-VAD.fmk. Second, activation of caspases is not essential for the initiation, commitment, or execution of cell death. Specifically, there was no activation of caspase-3, -8, and -9 upon anti-HLA-DR addition. Lastly, there was no cleavage of PARP, which is a hallmark of caspase-3 effector activity. Instead, we established that the addition of anti-HLA-DR caused a rapid dysfunction of the mitochondria, represented by the disruption of the DC m , which could be largely blocked by Bcl-2 overexpression. As a result, there is a selective release of AIF, but not cytochrome c, from the mitochondria into the cytosol. We also find that although Bcl-2 can inhibit the induction of phosphatidylserine exposure and that this inhibition is associated with blocking the collapse of the mitochondria membrane potential, the release of AIF is not as significantly blocked. Since the events that trigger AIF release have not been fully elucidated, it is possible that the Bcl-2 blockage of mitochondrial depolarization is downstream Hu1D10 treatment results in the release of AIF from the mitochondria. Raji cells were treated for various times with 2-5 mg/ml Hu1D10 or anti-CD95 (FAS). Cells were then briefly treated with 0.03% digitonin to permeabilize the outer membrane of the cells without affecting the mitochondrial membrane. Cells were then fixed with 4% paraformaldehyde and then incubated with an anti-AIF antibody that had been directly conjugated with the fluorophore Alexa 488. AIF release from the mitochondria was measured by flow cytometry.
Figure 7
Bcl-2 inhibits Hu1D10-mediated cell death. ALL-697 cells (697/Bcl-2 or mock-transfected 697/Neo) were treated with 10 mg/ml Hu1D10 or the negative control anti-Her-2. After 10 min, 10 mg/ml goat anti-human IgG was added to crosslink the antibodies and cells were incubated for up to 12 h. (a) Cells were stained with FITC-conjugated annexin V and PI. Flow cytometry was used to assess percentage of cell death (annexin V positive). (b) Alternatively, cells were stained with rhodamine 123 to assess changes in DC m as described in Figure 4 . of AIF release. It has similarly been shown that the translocation of cytochrome c out of the mitochondria does not require mitochondrial depolarization. 24 There has been evidence from many other experimental systems using pan-caspase inhibitors demonstrating that cell death can occur via a caspase-independent mechanism. Cell death induced by this pathway exhibits many of the stereotypical features of apoptosis. 9 Decrease in cell volume, changes in morphologic appearance, and progression through an annexin V-positive and PI-negative stage following anti-HLA-DR treatment are all observed, and yet this form of cell death revealed no requirement for caspase activity (Figures 2 and 3 and data not shown). Similarly, many recent studies showed triggering of certain surface receptors expressed on lymphocytes, such as MHC class I, CD2, CD4, CD45, CD47, and CD99, lead to a nonclassical form of cell death that acts independently of any of the known caspases. [25] [26] [27] [28] [29] [30] [31] AIF, a mitochondrial intermembrane flavoprotein, has recently been found to be an apoptosis mediator independent of caspases. 12, 13, 32 Microinjection of recombinant AIF into the cytoplasm of intact cells induces loss of DC m , exposure of phosphatidylserine on the plasma membrane, and chromatin condensation. 13 When added to purified nuclei, recombinant AIF causes caspase-independent cleavage of DNA into large fragments (450 kb). Interestingly, following treatment with anti-HLA-DR, the Raji cell nuclear morphology was also characterized by nuclear condensation without extensive oligonucleosomal DNA fragmentation, 10 leading us to hypothesize that AIF might play a role in anti-HLA-DR-induced cell death. Following the addition of anti-HLA-DR, we find that there is an immediate disruption of the mitochondria DC m , detectable within 10 min after the induction of apoptosis. This caspase-independent mitochondrial response results in the selective release and translocation of AIF from the intermembrane space of the mitochondria to the cytosol, in as early as 30 min after the initial apoptotic insult. This release is selective because cytochrome c is retained in the mitochondria, suggesting that the early release of AIF from the mitochondria is not indicative of an overall release of mitochondrial intermembrane proteins. This may seem counterintuitive considering that the formation of protein permeant pores in the mitochondrial membrane would likely prefer the release of small proteins like cytochrome c (14 kDa), as compared to large proteins like AIF (56 kDa). However, since cytochrome c is preferentially localized to the inner mitochondrial membrane via weak electrostatic interactions with molecules such as cardiolipin, cytochrome c might not be released during the nonsynchronous opening of the mitochondrial PT pores until there is a complete disruption of the inner membrane potential. [33] [34] [35] Therefore, the temporal relation between the release of AIF and cytochrome c from the mitochondria should be considered. It has been recently demonstrated that in anti-CD2-treated T cells, AIF is released from mitochondria exhibiting normal DC m , whereas cytochrome c is retained. 26 Cytochrome c is eventually released from the mitochondria of anti-CD2-treated cells, but the release was delayed as compared to that of AIF, and coincided with the collapse of DC m . Similarly, it has been recently demonstrated that AIF release precedes cytochrome c release in granulysininduced apoptosis in cytotoxic T lymphocytes. 36 Granulysin induces cell death utilizing two distinct pathways, one fast and the other slow. The fast pathway is caspase-independent and is associated with a rapid loss of DC m that temporally corresponds with AIF release. The slow pathway is evident after 12 h and can be blocked by pan-caspase inhibitors. The events that occur in the fast pathway resemble anti-HLA-DR-mediated cell death. It may be that the kinetics of anti-HLA-DR-mediated signaling is so rapid that mitochondria never reach complete DC m disruption to allow for the release of cytochrome c, but the initial disruption of the DC m by anti-HLA-DR is sufficient to selectively release AIF.
Anti-HLA-DR can induce cell death in the ALL cell line ALL-697 and its action can be partially inhibited by Bcl-2. The inhibition of HLA-DR-mediated cell death by Bcl-2 in ALL-697 is associated with better maintenance of the mitochondria membrane potential resulting in the diminished release of AIF from the mitochondria. From this data, it seems paradoxical that Hu1D10 appears to show some efficacy in the phase I trial of patients with follicular lymphoma, a disease mostly characterized by having a t(14;18) gene translocation and overexpression of Bcl-2. One possible explanation is that the combined action of HLA-DR-initiated signal transduction together with patient effector function is able to overcome cell death inhibition mediated by Bcl-2. The other possible explanation is that signals induced by anti-HLA-DR activate pro-apoptotic molecules or sequester anti-apoptotic molecules, which counter the action of Bcl-2 in follicular lymphoma. In anti-CD20-induced apoptosis of NHL cells, both induction of pro-apoptotic molecules and sequestering anti-apoptotic molecules have been observed. 37, 38 Future experiments to examine the proximal signaling pathways prior to cell death induced by anti-HLA-DR in NHL cells will be important to address these questions. The knowledge of the upstream signaling events may also allow us to rationally design combination treatment strategies to enhance the efficacy of HLA-DR-specific antibodies.
In conclusion, we find that anti-HLA-DR antibodies induce cell death in NHL cells and B-CLL cells utilizing a caspaseindependent pathway and the protein AIF appears to be the key mediator of HLA-DR-mediated cell death. The same mechanism seems to operate in cell lines as well as in cells isolated from B-CLL patients (Hu1D10 induces parallel cell death and survival signals involving reactive oxygen species in primary human CLL cells: a preclinical justification for combination studies with Hu1D10 and PI3 kinase inhibitors, Mone A, Aron JL, Lucas D, Cheney C, Bains SK, Tso JY, Green JM, Byrd JC, manuscript in preparation). 7 These data indicate that anti-HLA-DR antibodies can induce cell death in malignant B cells from patients and the killing mechanism induced by anti-HLA-DR antibodies is Bcl-2 inhibits the release of AIF from the mitochondria after Hu1D10 treatment. ALL-697 cells (697/Bcl-2 or mock-transfected 697/Neo) were treated with 10 mg/ml Hu1D10 or the negative control anti-Her2. After 10 min, 10 mg/ml goat anti-human IgG was added to crosslink the antibodies and cells were incubated for up to 24 h. Cells were stained to visualize AIF release as described in Figure 6 . medically relevant for lymphoma and leukemia treatment. Since this mechanism of action is different from that of other antibody therapies, HLA-DR-specific antibodies should complement or enhance the efficacy of treatment.
